Asco updates 2012

Many novel agents with different mechanisms of action are being explored [ 52 — 55 ]. It would be interesting to see whether adding novel agents to BR or R-CHOP can further improve the outcomes of advanced indolent lymphoma. Scand J Immunol. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Coiffier B: Rituximab in diffuse large B-cell lymphoma. Google Scholar. Coiffier B: Rituximab therapy in malignant lymphoma.

Anti-cancer drugs. Lancet Oncol. N Eng J Med. Nat Clin Pract Oncol. Semin Oncol. J Hematol Oncol. Johnson P: New targets for lymphoma treatment. Invest New Drugs. Leuk Lymphoma. CAS Google Scholar. Ann Hematol. Montillo M: Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial. Expert Rev Hematol. Leuk Res. Hematol Oncol. Journal of nuclear medicine: official publication, Society of Nuclear Medicine.

Article Google Scholar. Br J Cancer. Expert Rev Anticancer Ther. Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A: Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

Cancer Sci. Download references. You can also search for this author in PubMed Google Scholar. Correspondence to Delong Liu or Quanyi Lu. DL and QL designed the study. All authors participated in data collection and draft preparation. All authors read and approved the final manuscript. Pharmaceuticals Basel , 7 5 , 07 May To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Drugs , 63 8 , 01 Jan Cited by: articles PMID: J Clin Oncol , 36 7 , 02 Nov Cited by: 32 articles PMID: J Clin Oncol , 37 12 , 27 Feb Review Free to read. Keating GM. Drugs , 70 11 , 01 Jul Contact us. Europe PMC requires Javascript to function effectively.

Recent Activity. Search life-sciences literature Over 39 million articles, preprints and more Search Advanced search. This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Search articles by 'Jiangning Zhao'. Zhao J 1 ,. Search articles by 'Zhenshu Xu'. Search articles by 'Delong Liu'. Search articles by 'Quanyi Lu'. Affiliations 2 authors 1. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract Indolent lymphoma IL , the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain.

Free full text. Cancer Cell Int. Published online Aug PMID: Author information Article notes Copyright and License information Disclaimer. Corresponding author.

Jiangning Zhao: nc. Received Jul 16; Accepted Aug This article has been cited by other articles in PMC. Rituximab: study of pharmacokinetics PK and pharmacodynamics PD for faster infusion Rituximab R is typically infused over 4—6 hours. Gemcitabine, rituximab and oxaliplatin GROC Oxaliplatin has been studied for lymphoma therapy in various combination regimens [ 47 - 50 ].

Conclusions and future directions The optimal chemotherapy regimen for frontline therapy of advanced indolent lymphoma remains uncertain. Competing interests Authors have no relevant conflict of interest. Rituximab anti-CD20 therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.

Scand J Immunol. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Rituximab in diffuse large B-cell lymphoma. Rituximab therapy in malignant lymphoma. Rituximab anti-CD20 monoclonal antibody for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Aggressive lymphoma: improving treatment outcome with rituximab.

Anti-cancer drugs. Lancet Oncol. N Eng J Med. Nat Clin Pract Oncol. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.

J Hematol Oncol. New targets for lymphoma treatment. Targeted therapy in lymphoma. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. The clinical potential of microRNAs. The Four types of Tregs in malignant lymphomas.

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. Invest New Drugs. Palliative care has much to offer to manage quality-of-life concerns in cancer survivors.

Family caregivers are the key providers of patient care and need education, support, and skills preparedness; providers may refer caregivers of patients with early or advanced cancer to palliative care services. Patients participating in clinical trials can benefit from palliative care.

There is growing evidence of the cost benefits of palliative care, in addition to better quality of care and equal or longer survival. None of the information posted on ASCOconnection. The mention of any product, service, company, therapy or physician practice on ASCOconnection. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in, posted on, or linked to this site, or any errors or omissions.

Recent posts Subscribe to this column. Dec 06, Nov 16,